Inhibikase Therapeutics, Inc. Stock-Based Compensation
Inhibikase Therapeutics, Inc. (IKT) reported Stock-Based Compensation of $10.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.35M, a 27.02% increase year-over-year.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $5.56M, a 172.24% increase year-over-year.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $4.53M, a 42.67% decline year-over-year.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.53M, a 2957.08% increase year-over-year.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $15.31M, a 88.07% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $8.14M, a 1527.64% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $500.15K, a 9.17% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $458.15K, a 70.09% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $10.91M 10-Q · filed 2026-08-11 | $15.44M derived: sum of 3 quarters · filed 2026-08-11 | $19.96M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $5.56M 10-Q · filed 2026-05-12 | $10.09M derived: sum of 2 quarters · filed 2026-05-12 | $14.62M derived: sum of 3 quarters · filed 2026-05-12 | $18.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $9.06M derived: sum of 2 quarters · filed 2026-03-26 | $13.27M derived: sum of 3 quarters · filed 2026-08-11 | $15.31M 10-K · filed 2026-03-26 |
| 2025-09-30 | $4.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $8.73M derived: sum of 2 quarters · filed 2026-08-11 | $10.78M 10-Q · filed 2025-11-14 | $18.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $6.25M 10-Q · filed 2026-08-11 | $14.16M derived: sum of 3 quarters · filed 2026-08-11 | $14.31M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $2.04M 10-Q · filed 2026-05-12 | $9.95M derived: sum of 2 quarters · filed 2026-05-12 | $10.10M derived: sum of 3 quarters · filed 2026-05-12 | $10.13M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $8.06M derived: sum of 2 quarters · filed 2026-03-26 | $8.09M derived: sum of 3 quarters · filed 2026-03-26 | $8.14M 10-K · filed 2026-03-26 |
| 2024-09-30 | $148.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $178.72K derived: sum of 2 quarters · filed 2025-11-14 | $232.16K 10-Q · filed 2025-11-14 | $354.40K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $30.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $84.13K 10-Q · filed 2025-08-14 | $206.38K derived: sum of 3 quarters · filed 2025-08-14 | $336.16K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $53.43K 10-Q · filed 2025-05-14 | $175.68K derived: sum of 2 quarters · filed 2025-05-14 | $305.46K derived: sum of 3 quarters · filed 2025-05-14 | $430.31K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $122.25K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $252.03K derived: sum of 2 quarters · filed 2025-03-27 | $376.88K derived: sum of 3 quarters · filed 2025-03-27 | $500.15K 10-K · filed 2025-03-27 |
| 2023-09-30 | $129.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $254.63K derived: sum of 2 quarters · filed 2024-11-14 | $377.90K 10-Q · filed 2024-11-14 | $478.26K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $124.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $248.12K 10-Q · filed 2024-08-14 | $348.48K derived: sum of 3 quarters · filed 2024-08-14 | $450.27K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $123.27K 10-Q · filed 2024-05-15 | $223.64K derived: sum of 2 quarters · filed 2024-05-15 | $325.42K derived: sum of 3 quarters · filed 2024-05-15 | $458.19K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $100.36K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $202.15K derived: sum of 2 quarters · filed 2024-03-27 | $334.92K derived: sum of 3 quarters · filed 2024-03-27 | $458.15K 10-K · filed 2024-03-27 |
| 2022-09-30 | $101.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $234.56K derived: sum of 2 quarters · filed 2023-11-14 | $357.78K 10-Q · filed 2023-11-14 | $623.63K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $132.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $256.00K 10-Q · filed 2023-08-14 | $521.85K derived: sum of 3 quarters · filed 2023-08-14 | $874.26K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $123.23K 10-Q · filed 2023-05-15 | $389.08K derived: sum of 2 quarters · filed 2023-05-15 | $741.50K derived: sum of 3 quarters · filed 2023-05-15 | $1.06M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $265.85K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $618.27K derived: sum of 2 quarters · filed 2023-03-31 | $940.75K derived: sum of 3 quarters · filed 2023-03-31 | $1.53M 10-K · filed 2023-03-31 |
| 2021-09-30 | $352.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $674.90K derived: sum of 2 quarters · filed 2022-11-14 | $1.27M 10-Q · filed 2022-11-14 | $1.42M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $322.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $913.61K 10-Q · filed 2022-08-12 | $1.07M derived: sum of 3 quarters · filed 2022-08-12 | $1.21M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $591.12K 10-Q · filed 2022-05-16 | $745.54K derived: sum of 2 quarters · filed 2022-05-16 | $885.30K derived: sum of 3 quarters · filed 2022-05-16 | $1.03M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $154.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $294.18K derived: sum of 2 quarters · filed 2022-03-31 | $433.94K derived: sum of 3 quarters · filed 2022-03-31 | $573.70K 10-K · filed 2022-03-31 |
| 2020-09-30 | $139.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $279.52K derived: sum of 2 quarters · filed 2021-11-15 | $419.27K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $139.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $279.52K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $139.76K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |